JP2016528202A - 小児患者の脈絡網膜血管新生障害および透過性障害の治療におけるｖｅｇｆアンタゴニストの使用 - Google Patents

小児患者の脈絡網膜血管新生障害および透過性障害の治療におけるｖｅｇｆアンタゴニストの使用 Download PDF

Info

Publication number
JP2016528202A
JP2016528202A JP2016524930A JP2016524930A JP2016528202A JP 2016528202 A JP2016528202 A JP 2016528202A JP 2016524930 A JP2016524930 A JP 2016524930A JP 2016524930 A JP2016524930 A JP 2016524930A JP 2016528202 A JP2016528202 A JP 2016528202A
Authority
JP
Japan
Prior art keywords
vegf antagonist
vegf
dose
child
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016524930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528202A5 (enExample
Inventor
アクゼノヴ，セルゲイ
ブリアン，ガブリエラ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2016528202A publication Critical patent/JP2016528202A/ja
Publication of JP2016528202A5 publication Critical patent/JP2016528202A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2016524930A 2013-07-11 2014-07-09 小児患者の脈絡網膜血管新生障害および透過性障害の治療におけるｖｅｇｆアンタゴニストの使用 Pending JP2016528202A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845064P 2013-07-11 2013-07-11
US61/845,064 2013-07-11
PCT/IB2014/062978 WO2015004616A1 (en) 2013-07-11 2014-07-09 Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients

Publications (2)

Publication Number Publication Date
JP2016528202A true JP2016528202A (ja) 2016-09-15
JP2016528202A5 JP2016528202A5 (enExample) 2017-08-10

Family

ID=51211282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524930A Pending JP2016528202A (ja) 2013-07-11 2014-07-09 小児患者の脈絡網膜血管新生障害および透過性障害の治療におけるｖｅｇｆアンタゴニストの使用

Country Status (11)

Country Link
US (2) US20160168240A1 (enExample)
EP (1) EP3019526A1 (enExample)
JP (1) JP2016528202A (enExample)
KR (1) KR20160029794A (enExample)
CN (1) CN105377891A (enExample)
AU (2) AU2014288837A1 (enExample)
BR (1) BR112016000177A2 (enExample)
CA (1) CA2917807A1 (enExample)
MX (1) MX2016000384A (enExample)
RU (1) RU2676274C2 (enExample)
WO (1) WO2015004616A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022184907A (ja) * 2017-05-01 2022-12-13 オーハイ レチナル テクノロジー，エルエルシー 近視の治療のためのシステムおよびプロセス

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
BRPI1006897A2 (pt) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compostos, composições e métodos de prevenção da metástase de células cancerosas.
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
WO2015173260A1 (en) * 2014-05-12 2015-11-19 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
US20180326126A1 (en) * 2015-11-18 2018-11-15 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
CN108697792A (zh) * 2015-11-19 2018-10-23 珠海泰瑞尚生物医药科技有限公司 用于结合vegf的方法和组合物
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CN109310756B (zh) * 2016-05-13 2022-06-28 奥美药业有限公司 新型血管生成素2，vegf双特异性拮抗剂
SG10201912556VA (en) 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
EP3573641A4 (en) * 2017-01-25 2020-11-11 Iconic Therapeutics, Inc. TREATMENT METHODS FOR DISORDERS ASSOCIATED WITH ANGIOGENESIS AND NEOVASCULARIZATION
AU2018370135A1 (en) * 2017-11-16 2020-06-04 Iveric Bio, Inc. A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (IPCV)
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
JP7564824B2 (ja) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3157394A1 (en) * 2019-12-19 2021-06-24 Helena ERIKSSON Compounds for treatment of eye diseases associated with excessive vascularisation
RU2762991C1 (ru) * 2021-09-06 2021-12-24 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения макулярного отека вследствие окклюзии ветви центральной вены сетчатки в сочетании с ретинальной артериолярной макроаневризмой
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
EP4761750A1 (en) * 2023-08-17 2026-06-24 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating age-related macular degeneration and diabetic macular edema
CN118085112B (zh) * 2024-04-29 2024-08-09 上海鼎新基因科技有限公司 抗多个vegf家族蛋白的融合蛋白及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072933A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
JP2011513229A (ja) * 2008-02-21 2011-04-28 イスタ・ファーマスーティカルズ・インコーポレイテッド 補助剤としての眼科用ｎｓａｉｄ
JP2012507271A (ja) * 2008-11-03 2012-03-29 モレキュラー・パートナーズ・アーゲー Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質
JP2012512184A (ja) * 2008-12-16 2012-05-31 キュー エル ティー インク． 眼の状態に関する光線力学的療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316394B1 (en) 2001-06-12 2016-11-23 The Johns Hopkins University Reservoir device for intraocular drug delivery
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
ES2381014T3 (es) 2004-06-08 2012-05-22 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína quimérica inhibidora de la angiogénesis y el uso
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
CN102215875B (zh) * 2008-10-16 2014-08-06 凯瑟琳·科根·法瑞纳斯 持续药物递送系统
CA2757037C (en) 2009-01-29 2019-08-06 Forsight Vision4, Inc. Posterior segment drug delivery
JP2012525415A (ja) * 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072933A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
JP2011513229A (ja) * 2008-02-21 2011-04-28 イスタ・ファーマスーティカルズ・インコーポレイテッド 補助剤としての眼科用ｎｓａｉｄ
JP2012507271A (ja) * 2008-11-03 2012-03-29 モレキュラー・パートナーズ・アーゲー Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質
JP2012512184A (ja) * 2008-12-16 2012-05-31 キュー エル ティー インク． 眼の状態に関する光線力学的療法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ACTA OPHTHALMOL., vol. 90, no. 7, JPN5016007785, 17 February 2012 (2012-02-17), pages 574 - 575, ISSN: 0003999946 *
ARCH OPHTHALMOL., vol. 126, no. 8, JPN6018015030, 2008, pages 1152 - 1156, ISSN: 0003999947 *
CAN. J. OPHTHALMOL., vol. 46, no. 1, JPN5016007788, 1 February 2011 (2011-02-01), pages 46 - 50, ISSN: 0003999949 *
J. AAPOS, vol. 13, no. 6, JPN5016007787, 1 December 2009 (2009-12-01), pages 616 - 617, ISSN: 0003999948 *
LUCENTIS (RANIBIZUMAB INJECTION) INTRAVITREAL INJECTION (LABEL), JPN6018015031, 2012, pages 6 - 14, ISSN: 0003999950 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022184907A (ja) * 2017-05-01 2022-12-13 オーハイ レチナル テクノロジー，エルエルシー 近視の治療のためのシステムおよびプロセス

Also Published As

Publication number Publication date
KR20160029794A (ko) 2016-03-15
RU2676274C2 (ru) 2018-12-27
MX2016000384A (es) 2016-04-29
CN105377891A (zh) 2016-03-02
CA2917807A1 (en) 2015-01-15
EP3019526A1 (en) 2016-05-18
US20160168240A1 (en) 2016-06-16
RU2016104397A (ru) 2017-08-16
BR112016000177A2 (pt) 2017-12-12
WO2015004616A1 (en) 2015-01-15
RU2016104397A3 (enExample) 2018-05-31
US20180194835A1 (en) 2018-07-12
AU2017203923B2 (en) 2018-10-18
AU2017203923A1 (en) 2017-07-06
AU2014288837A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
AU2017203923B2 (en) Use of a VEGF antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
JP7668858B2 (ja) チロシンキナーゼ阻害剤を含む眼内インプラント
Zhang et al. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys
JP2016523956A (ja) 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用
JP2015528454A (ja) 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用
JP2016522249A (ja) 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用
JP2023099094A (ja) 眼科疾患の処置
JP7730816B2 (ja) 過剰血管新生に関連する眼疾患を治療する化合物
JP2016522250A (ja) 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用
JP7828274B2 (ja) 眼疾患を治療するための方法
JP2016522248A (ja) ポリープ状脈絡膜血管症の治療
Ansari et al. Diabetic Eye Diseases
BR112022018815B1 (pt) Implante ocular contendo um inibidor de tirosina cinase, seus métodos de preparação, e usos
EA046420B1 (ru) Применение антагониста vegf для лечения ангиогенных глазных заболеваний

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190319